834 related articles for article (PubMed ID: 15943841)
1. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
5. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
[TBL] [Abstract][Full Text] [Related]
6. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Bautista J; Fullerton H; Briseno M; Cui H; Fass R
Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Eskes SA; Meuwissen SG
Am J Gastroenterol; 1999 Apr; 94(4):884-7. PubMed ID: 10201451
[TBL] [Abstract][Full Text] [Related]
8. Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production.
Bergman MP; Klinkenberg-Knol EC; Faller G; Aar A; Lakhai W; Vandenbroucke-Grauls CM; Kuipers EJ; Appelmelk BJ
Aliment Pharmacol Ther; 2005 Apr; 21(8):977-83. PubMed ID: 15813833
[TBL] [Abstract][Full Text] [Related]
9. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.
Wiklund I; Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir D; Fulton C; Gillon K; Peacock R
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):19-27. PubMed ID: 9615259
[TBL] [Abstract][Full Text] [Related]
10. Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors?
Rauws EA
Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):569-73. PubMed ID: 9513835
[TBL] [Abstract][Full Text] [Related]
11. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia.
Vakil N; Talley NJ; Stolte M; Sundin M; Junghard O; Bolling-Sternevald E
Aliment Pharmacol Ther; 2006 Jul; 24(1):55-63. PubMed ID: 16803603
[TBL] [Abstract][Full Text] [Related]
12. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
Carlsson R; Dent J; Watts R; Riley S; Sheikh R; Hatlebakk J; Haug K; de Groot G; van Oudvorst A; Dalväg A; Junghard O; Wiklund I
Eur J Gastroenterol Hepatol; 1998 Feb; 10(2):119-24. PubMed ID: 9581986
[TBL] [Abstract][Full Text] [Related]
13. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W
Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740
[TBL] [Abstract][Full Text] [Related]
15. Carditis: all Helicobacter pylori or is there a role for gastro-oesophageal reflux?
McNamara D; Buckley M; Crotty P; Hall W; O'Sullivan M; O'Morain C
Scand J Gastroenterol; 2002 Jul; 37(7):772-7. PubMed ID: 12190089
[TBL] [Abstract][Full Text] [Related]
16. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.
Lundell L; Havu N; Miettinen P; Myrvold HE; Wallin L; Julkunen R; Levander K; Hatlebakk JG; Liedman B; Lamm M; Malm A; Walan A;
Aliment Pharmacol Ther; 2006 Mar; 23(5):639-47. PubMed ID: 16480403
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
18. Review article: Helicobacter pylori and gastro-oesophageal reflux disease.
Delaney B; McColl K
Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():32-40. PubMed ID: 16042657
[TBL] [Abstract][Full Text] [Related]
19. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
20. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease.
Størdal K; Johannesdottir GB; Bentsen BS; Knudsen PK; Carlsen KC; Closs O; Handeland M; Holm HK; Sandvik L
Arch Dis Child; 2005 Sep; 90(9):956-60. PubMed ID: 16113133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
